19-23649-shl Doc 769 Filed 01/22/20 Entered 01/22/20 16:40:50 Main Document Pg 1 of 7

19-23649-rdd Doc 128-1 Filed 09/26/19 Entered 09/26/19 19:00:23 Exhibit A-Proposed Order Pg 13 of 19

UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK				
In re:	Chapter 11			
PURDUE PHARMA L.P., et al.,	Case No. 19-23649 (RDD)			
Debtors.1	(Jointly Administered)			
AFFIDAVIT AND DISCLOSURE STATEMENT OF Keely E. Duke ON BEHALF OF Duke Scanlan & Hall, PLLC STATE OF Idaho) s.s.: COUNTY OF Ada)				
Keely E. Duke_, being duly sworn,	upon his oath, deposes and says as follows:			

- 2. Purdue Pharma L.P. and its affiliates that are debtors and debtors in possession in the above-captioned chapter 11 cases (collectively, the "**Debtors**"), have requested that the Firm provide services to the Debtors, and the Firm has consented to provide such services (the "**Services**").
- 3. The Services include, but are not limited to, the following: <u>legal representation</u> of Purdue Pharma L.P. and its affiliates in civil litigation in Idaho, including State of Idaho, Fourth Judicial District, Ada County Case No. CV01-19-10061.

I am a member of Duke Scanlan & Hall, PLLC .

_(the "Firm").

1.

located at 1087 W. River St., Ste. 300, Boise, ID 83702

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

19-23649-shl Doc 769 Filed 01/22/20 Entered 01/22/20 16:40:50 Main Document Pg 2 of 7
19-23649-rdd Doc 128-1 Filed 09/26/19 Entered 09/26/19 19:00:23 Exhibit A-Proposed Order Pg 14 of 19

- 4. The Firm may have performed services in the past and may perform services in the future, in matters unrelated to these chapter 11 cases, for persons that are parties in interest in the Debtors' chapter 11 cases. As part of its customary practice, the Firm is retained in cases, proceedings, and transactions involving many different parties, some of whom may represent or be claimants or employees of the Debtors, or other parties in interest in these chapter 11 cases. The Firm does not perform services for any such person in connection with these chapter 11 cases. In addition, the Firm does not have any relationship with any such person, such person's attorneys, or such person's accountants that would be adverse to the Debtors or their estates with respect to the matters on which the Firm is to be retained.
- 5. Neither I, nor any principal of, or professional employed by the Firm has agreed to share or will share any portion of the compensation to be received from the Debtors with any other person other than principals and regular employees of the Firm.
- 6. Neither I nor any principal of, or professional employed by the Firm, insofar as I have been able to ascertain, holds or represents any interest materially adverse to the Debtors or their estates with respect to the matters on which the Firm is to be retained.

19-23649-shl Doc 769 Filed 01/22/20 Entered 01/22/20 16:40:50 Main Document Pg 3 of 7

19-23649-rdd Doc 128-1 Filed 09/26/19 Entered 09/26/19 19:00:23 Exhibit A-Proposed Order Pg 15 of 19

- 7. As of the commencement of this chapter 11 case, the Debtors owed the Firm \$_17,005.00 in respect of prepetition services rendered to the Debtors.
- 8. The Firm is conducting further inquiries regarding its retention by any creditors of the Debtors, and upon conclusion of this inquiry, or at any time during the period of its employment, if the Firm should discover any facts bearing on the matters described herein, the Firm will supplement the information contained in this Affidavit.

Pursuant to 28 U.S.C. § 1746, I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct, and that this Affidavit and Disclosure Statement was executed on December 6, 2019, ap 4:000.......

SWORN TO AND SUBSCRIBED before Methis of December 2019

Notary Public



UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK	1			
In re:	Chapter 11			
PURDUE PHARMA L.P., et al.,	Case No. 19-23649 (RDD)			
Debtors. ¹	(Jointly Administered)			
RETENTION QUESTIONNAIRE TO BE COMPLETED BY PROFESSIONALS EMPLOYED by Purdue Pharma L.P. and its affiliates that are debtors and debtors in possession in the above-captioned cases (collectively, the "Debtors"). All questions must be answered. Please use "none," "not applicable," or "N/A," as appropriate. If more space is needed, please complete on a separate page and attach.				
1. Name and address of professional:				
Duke Scanlan & Hall, PLLC; 1087 W. Riv	ver St., Ste. 300, Boise, ID 83702			
2. Date of retention: <u>July 12, 2019.</u>				

3.

Type of services to be provided:

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

19-23649-shl Doc 769 Filed 01/22/20 Entered 01/22/20 16:40:50 Main Document Pg 5 of 7

<u>Legal Services</u>
Brief description of services to be provided:
Representation in civil matters brought in the State of Idaho, including, but not
limited to the defense of State of Idaho, Fourth Judicial District, Ada County Case
No. CV01-19-10061.
Arrangements for compensation (hourly, contingent, etc.):
Hourly rate, plus costs.
(a) Average hourly rate (if applicable): \$275/hour
(b) Estimated average monthly compensation based on prepetition retention (if company was employed prepetition):
\$68,000.00
Prepetition claims against the Debtors held by the company:
Amount of claim: \$17,005.00
Date claim arose: September 14, 2019.
Nature of claim: Outstanding prepetition legal expenses.

19-23649-shl Doc 769 Filed 01/22/20 Entered 01/22/20 16:40:50 Main Document Pg 6 of 7

Prepetition claims against the Debtors held individually by any member associate, or employee of the company:			
Name: <u>n/a</u>			
Status:			
Amount of claim: \$			
Date claim arose:			
Nature of claim:			
Disclose the nature and provide a brief description of any interest adverse to the Debtors or to their estates for the matters on which the professional is to be employed:			
We are aware of no interests adverse to the debtors or their estates at this time			
with respect to matters upon which Duke Scanlan & Hall, PLLC has been			
employed.			
Disclose whether the professional currently represents any of the Debtors existing shareholders, including trusts, beneficiaries, companies, affiliates, family members and any similar related parties (together, the "Shareholder Parties") and/or any entity owned or controlled by any Shareholder Party (in each case other than any Debtor), and whether any Shareholder Party or any entity owned o controlled by any Shareholder Party (other than any Debtor) accounted for more than 1% of the professionals' annual revenue for any of the last five years. If so describe what ethical walls or other protections are in place with regard to the			

Duke Scanlan & Hall, PLLC is not engaged in the representation of any of the

concurrent representations.

19-23649-shl Doc 769 Filed 01/22/20 Entered 01/22/20 16:40:50 Main Document Pg 7 of 7

Debtors' existing shareholders.
Name and title of individual completing this form:
Keely E. Duke; Member; Duke Scanlan & Hall, PLLC.

Dated: December 8, 2019